1033.1000 -1.40 (-0.14%)
NSE Sep 17, 2025 10:14 AM
Volume: 97,128
 

1033.10
-0.14%
Motilal Oswal
Gross margin stood at 62.9% and contracted 380bp YoY on high base of past year. EBITDA margin at 21.4%, contracted 540bp YoY, largely due to change in product mix and higher other expenses as % of sales (+130bp YoY). Absolute EBITDA at INR8b (our est. INR7.2b) was down 8% YoY. PAT came in at INR4.6b (our est. INR3.9b), down 24% YoY. In FY19, sales/EBITDA/PAT stood at INR131b/INR30b/INR18.7b up 10%/5%/4% YoY. Key Con-call highlights: (a) Despite high base of FY19 witnessed in US sales, CDH guided to maintain business to remain at similar levels (USD900m) in...
Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended